# Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

> **NCT00562614** · PHASE2 · COMPLETED · sponsor: **Retension Pharmaceuticals. Inc.** · enrollment: 38 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** SLx-2101

## Key facts

- **NCT ID:** NCT00562614
- **Lead sponsor:** Retension Pharmaceuticals. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562614, "Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00562614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*